Publications
NIBIOs employees contribute to several hundred scientific articles and research reports every year. You can browse or search in our collection which contains references and links to these publications as well as other research and dissemination activities. The collection is continously updated with new and historical material.
2018
Sammendrag
No abstract has been registered
Sammendrag
No abstract has been registered
Forfattere
Even Klyve Dahl Hetron Mweemba Munang'andu Andre van Eerde Jihong Liu Clarke Øystein EvensenSammendrag
No abstract has been registered
Forfattere
Andre van Eerde Johanna Gottschamel Ralph Bock Kristine Eraker Aasland Hansen Hetron Mweemba Munangandu Henry Daniell Jihong Liu ClarkeSammendrag
Dengue fever is a mosquito (Aedes aegypti) ‐transmitted viral disease that is endemic in more than 125 countries around the world. There are four serotypes of the dengue virus (DENV 1‐4) and a safe and effective dengue vaccine must provide protection against all four serotypes. To date, the first vaccine, Dengvaxia (CYD‐TDV), is available after many decades’ efforts, but only has moderate efficacy. More effective and affordable vaccines are hence required. Plants offer promising vaccine production platforms and food crops offer additional advantages for the production of edible human and animal vaccines, thus eliminating the need for expensive fermentation, purification, cold storage and sterile delivery. Oral vaccines can elicit humoral and cellular immunity via both the mucosal and humoral immune systems. Here, we report the production of tetravalent EDIII antigen (EDIII‐1‐4) in stably transformed lettuce chloroplasts. Transplastomic EDIII‐1‐4‐expressing lettuce lines were obtained and homoplasmy was verified by Southern blot analysis. Expression of EDIII‐1‐4 antigens was demonstrated by immunoblotting, with the EDIII‐1‐4 antigen accumulating to 3.45% of the total protein content. Immunological assays in rabbits showed immunogenicity of EDIII‐1‐4. Our in vitro gastrointestinal digestion analysis revealed that EDIII‐1‐4 antigens are well protected when passing through the oral and gastric digestion phases but underwent degradation during the intestinal phase. Our results demonstrate that lettuce chloroplast engineering is a promising approach for future production of an affordable oral dengue vaccine.
Sammendrag
No abstract has been registered
Sammendrag
No abstract has been registered
Forfattere
Mihaela-Olivia Dobrica Catalin Lazar Lisa Paruch Andre van Eerde Jihong Liu Clarke Catalin Tucureanu Iuliana Caras Sonya Ciulean Adrian Onu Vlad Tofan Alexandru Branzan Stephan Urban Crina Stavaru Norica Branza-NichitaSammendrag
Hepatitis B Virus (HBV) infection can be prevented by vaccination. Vaccines containing the small (S)envelope protein are currently used in universal vaccination programs and achieve protective immuneresponse in more than 90% of recipients. However, new vaccination strategies are necessary for successfulimmunization of the remaining non- or low-responders. We have previously characterized a novel HBVchimeric antigen, which combines neutralization epitopes of the S and the preS1 domain of the large (L)envelope protein (genotype D). The S/preS121–47chimera produced in mammalian cells and Nicotianabenthamiana plants, induced a significantly stronger immune response in parenterally vaccinated micethan the S protein. Here we describe the transient expression of the S/preS121–47antigen in an edibleplant, Lactuca sativa, for potential development of an oral HBV vaccine. Our study shows that oral admin-istration of adjuvant-free Lactuca sativa expressing the S/preS121–47antigen, three times, at 1lg/dose,was sufficient to trigger a humoral immune response in mice. Importantly, the elicited antibodies wereable to neutralize HBV infection in an NTCP-expressing infection system (HepG2-NTCP cell line) moreefficiently than those induced by mice fed on Lactuca sativa expressing the S protein. These results sup-port the S/preS121–47antigen as a promising candidate for future development as an edible HBV vaccine.
Forfattere
Yanliang Wang Erik Lysøe Tegan Armarego-Marriott Alexander Erban Lisa Paruch Andre van Eerde Ralph Bock Jihong Liu ClarkeSammendrag
No abstract has been registered
Forfattere
Tonje Økland Jørn-Frode Nordbakken Holger Lange Ingvald Røsberg Kjersti Holt Hanssen Nicholas ClarkeSammendrag
No abstract has been registered
Sammendrag
No abstract has been registered